查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008910

卵巢癌市場報告：按類型、治療方法、最終用戶和地區分類（2026-2034 年）

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球卵巢癌市場規模達25億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到58億美元，2026年至2034年的複合年成長率（CAGR）為9.21%。北美地區憑藉其先進的醫療基礎設施、強大的科研能力以及對創新治療方法的旺盛需求，正引領市場成長。卵巢癌發生率的上升、癌症治療中個人化醫療的興起以及政府主導的旨在提高公眾意識、促進早期檢測和支持研究的各項舉措，都是推動市場成長的關鍵因素。

卵巢癌是一種發生在卵巢的癌症，卵巢是女性的生殖器官，負責產生卵子和雌激素。卵巢癌通常是由於卵巢內的異常細胞不受控制地增殖並形成腫瘤而引起的。卵巢癌有多種類型，根據其起源細胞的不同進行分類。最常見的類型是上皮性卵巢癌，它起源於卵巢表面。其他相對罕見的類型包括生殖細胞腫瘤和間質腫瘤，它們分別起源於產生卵子和荷爾蒙的細胞。卵巢癌的常見症狀包括腹脹、骨盆和腹部疼痛、食慾不振或容易飽腹、頻尿以及排便習慣改變。

標靶治療、免疫療法和個人化醫療的進步正在拓展治療選擇。這些治療方法比傳統化療更有效、副作用更少，從而改善了患者的預後。此外，臨床試驗的進展正在推動創新，促使新治療方法的研發，為提高患者的存活率和生活品質帶來了希望。同時，製藥公司、研究機構和非營利組織之間的合作也在推動卵巢癌治療的進步。這種合作匯集了資源和專業知識，以改善藥物研發、臨床試驗和宣傳活動。團隊合作能夠迅速將研究成果轉化為有效的治療方法，並改善卵巢癌治療的整體市場前景。此外，人們對卵巢癌的認知不斷提高，從而實現了早期診斷，這對於提高存活率至關重要。健康宣傳宣傳活動和計劃團體正在向人們普及症狀和風險因素，鼓勵更多女性就醫。早期篩檢技術的改進提高了現有治療方法的有效性。

卵巢癌市場趨勢：

擴大醫療保健投資和政府主導的舉措

世界各國政府日益認知到癌症影響的不斷擴大，並增加對癌症研究、治療舉措和創新醫療技術發展的投入。這些投資正在加速卵巢癌新療法、診斷設備和先進調查方法的研發。此外，製藥公司、生技公司和學術機構之間的夥伴關係正在加速新治療方法的發現。這些合作正在創造更具針對性、個人化和高效的治療方案。同時，資金支持的增加正在加速臨床試驗的發展和創新治療方法的快速實用化。這些合作努力將改善患者照護，提高存活率，並為持續研究提供更多資源，最終促進卵巢癌市場的成長並改善患者的治療效果。

標靶治療和新治療標準的核准

標靶治療的引入以及針對特定卵巢癌亞型的新治療標準的建立正在推動市場成長。我們對卵巢癌遺傳和分子基礎的認知不斷加深，促使人們開發出針對特定突變的治療方法，為患者提供更有效的治療選擇。在臨床試驗中展現出良好療效並獲得監管部門核准的新治療方法，正在提供更個人化和精準的治療，從而改善患者的預後。標靶治療的這些進展提高了存活率，同時也增加了對專業治療的需求，進一步推動了卵巢癌產業的成長和投資。 2025年5月，美國食品藥物管理局（FDA）核准了Verastem Oncology公司用於治療KRAS突變型低度漿液性卵巢（LGSOC）的聯合治療，使其成為首個獲準用於治療這種罕見癌症的治療方法。在II期臨床試驗中，abutometinib和defactinib的聯合治療顯示出44%的客觀緩解率。此次核準確立了該療法作為KRAS突變型複發性LGSOC新標準治療方案的地位。

研究進展和治療方案

創新治療方法的不斷進步顯著推動了卵巢癌市場的成長，提高了治療效果和患者預後。標靶治療、免疫療法和個人化醫療的進步為患者提供了更個人化和有效的治療選擇。這些進步提高了存活率和治療效果，從而促進了市場成長。此外，生物標記和基因譜分析的研究使得更有針對性和更及時的治療成為可能，進而加速了卵巢癌治療的市場參與和資金籌措。 2025年，Tilt Biotherapeutics公司在B輪資金籌措中籌集了2,260萬歐元（2,560萬美元），用於推進其腫瘤病毒療法「TILT-123」進入含鉑類藥物抗藥性卵巢癌（PROC）的II期臨床試驗。此治療方法與默克公司的「Keytruda」等T細胞治療方法合併使用，初步結果令人鼓舞，64%的病患病情得到控制。

卵巢癌市場成長要素：

擴大綜合癌症篩檢計劃

全面癌症篩檢舉措的推廣是卵巢癌市場的主要驅動力。這些計劃著重於癌症的早期發現，從而提高治療成功率並改善患者預後。透過整合性別特異性診斷、遺傳性癌症風險評估和腫瘤標記檢測，這些計劃提供了一種全面的癌症檢測策略。隨著人們對早期發現重要性的認知不斷提高，對便利且經濟實惠的篩檢方案的需求日益成長，尤其是在癌症發病率不斷上升的地區。擴大篩檢服務的覆蓋範圍不僅有助於早期療育，還能擴大診斷工具的市場，並推動卵巢癌領域創新產品和服務的需求。 2025年，Metropolis Healthcare推出了TruHealth Cancer Screen 360，這是一個旨在提高印度早期癌症檢測率的全面癌症篩檢方案。此方案包含性別特異性診斷、遺傳性癌症風險分析以及多種癌症的腫瘤標記檢測。該計劃旨在透過提高篩檢的可近性和可負擔性，來應對日益嚴重的癌症負擔，尤其是在都市區和都市區。

基因檢測和風險評估計劃的興起

日益重視識別具有遺傳易感性的個體，有助於更早發現疾病並採取個人化的預防措施。這種向預防性醫療保健的轉變，使得有針對性的干涉成為可能，從而改善治療效果，並最終降低發病率。隨著基因檢測的普及，尤其是在高風險族群及其家庭中，對相關診斷服務、治療和教育資源的需求也日益成長。此外，這些努力將幫助患者做出明智的健康選擇，最終透過提高公眾意識和擴大早期檢測工具的獲取途徑，促進市場成長。 2024年，史丹佛大學醫學院收到Bright Pink的350萬美元遺贈，用於推出Bright Pink預防風險推廣和級聯檢測（PROACT）計畫。該計畫專注於高風險族群及其家庭，旨在推廣乳癌和卵巢癌的基因檢測。該計畫建立在Bright Pink以往工作的基礎上，旨在改善基因風險評估的可近性，並支持積極主動的健康管理。

人工智慧驅動的癌症研究進展

人工智慧 (AI) 在卵巢癌研究中的應用，透過提升早期檢測能力、最佳化個人化治療策略並加速研究進展，正在推動市場成長。 AI 技術能夠分析大規模資料集，揭示以往難以發現的模式和洞見。透過利用機器學習 (ML) 演算法處理患者數據，研究人員可以開發更精準的診斷工具、改進治療通訊協定並預測患者預後。隨著 AI 不斷革新調查方法，治療效果和存活率的提高將增加對創新癌症治療方案的需求，從而進一步推動市場成長。 2025 年，全球卵巢癌研究聯盟與微軟「AI for Good Lab」合作，推出了一項 100 萬美元的「AI 加速器津貼」。該計劃旨在利用 AI 技術提高卵巢癌存活率並推進相關研究。該津貼將用於支持跨國跨領域研究團隊，共同應對全球卵巢癌危機。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球卵巢癌市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 上皮性卵巢癌
  • 生殖細胞卵巢卵巢
  • 卵巢間質細胞卵巢

第7章 市場區隔：依治療類型分類

  • 免疫療法
  • 化療
  • 標靶治療
  • 外科手術
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 居家照護
  • 專業醫療中心
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A6407

The global ovarian cancer market size reached USD 2.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2034, exhibiting a growth rate (CAGR) of 9.21% during 2026-2034. North America leads the market attributed to its advanced healthcare infrastructure, strong research capabilities, and high demand for innovative treatment options. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The development of targeted treatments, immune therapies, and individualized medicine is broadening therapeutic choices. These therapies are more efficient and less harmful than conventional chemotherapy, enhancing patient results. Moreover, advancements in clinical trials are fostering innovation, encouraging new treatments that provide optimism for improved survival rates and enhanced quality of life for patients. Besides this, collaborative partnerships among pharmaceutical firms, research organizations, and non-profit entities are driving advancements in ovarian cancer therapies. These collaborations improve drug development, clinical trials, and awareness initiatives by combining resources and expertise. Teamwork accelerates the translation of research into effective treatments and enhances the overall market outlook for ovarian cancer treatment. Furthermore, the growing awareness about ovarian cancer is leading to earlier diagnosis, which is essential for enhancing survival rates. Health campaigns and advocacy organizations are informing individuals about symptoms and risk elements, encouraging more women to pursue medical consultation. Timely detection via enhanced screening methods boosts the efficacy of current therapies.

OVARIAN CANCER MARKET TRENDS:

Increased Healthcare Investments and Government Initiatives

Governments around the globe, are becoming more aware about the increasing impact of cancer, are directing additional resources towards research, treatment initiatives, and the advancement of innovative medical technologies. These investments facilitate the discovery of novel therapeutic strategies, improved diagnostic instruments, and refined treatment methodologies for ovarian cancer. In addition, partnerships among pharmaceutical companies, biotech organizations, and academic institutions are speeding up the identification of new treatments. These collaborations result in the creation of more focused, individualized, and efficient treatment alternatives. Apart from this, the heightened financial backing promotes the growth of clinical trials and the swift commercialization of innovative therapies. This collaborative endeavor boosts patient care, increases survival rates, and guarantees that additional resources are accessible for ongoing research, ultimately contributing to the growth of the ovarian cancer market and enhancing patient outcomes.

Approval of Targeted Therapies and New Treatment Standards

The introduction of targeted therapies and the creation of new treatment benchmarks for particular ovarian cancer subtypes are bolstering the market growth. Progress in comprehending the genetic and molecular foundations of ovarian cancer is resulting in the creation of therapies that focus on particular mutations, providing patients with more effective treatment choices. With new therapies showing encouraging effectiveness in clinical trials and receiving regulatory approval, they offer more tailored and accurate care, enhancing patient outcomes. This advancement in targeted therapies is increasing survival rates while also generating higher demand for specialized treatments, driving further growth and investment in the ovarian cancer industry. In May 2025, the FDA approved Verastem Oncology's drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations, marking the first treatment for this rare cancer. The combination of avutometinib and defactinib showed a 44% response rate in a Phase 2 study. This approval sets the therapy as the new standard of care for recurrent LGSOC with KRAS mutations.

Advancements in Research and Treatment Options

The continuous advancement of innovative therapies is significantly driving the growth of the ovarian cancer market by improving treatment efficacy and patient outcomes. Advances in targeted treatments, immunotherapy, and personalized medicine offer patients more customized and effective options for therapy. These developments enhance survival rates and treatment effectiveness, contributing to the market growth. Besides this, studies on biomarkers and genetic profiling are resulting in more targeted and timely treatments, which consequently enhances market engagement and funding in ovarian cancer therapies. In 2025, Tilt Biotherapeutics raised €22.6 million ($25.6 million) in Series B funding to advance its oncolytic virus therapy, TILT-123, into a Phase II trial for platinum-resistant ovarian cancer (PROC). The therapy, combined with T cell-based treatments like Merck's Keytruda, showed promising early results, with 64% of patients achieving disease control.

OVARIAN CANCER MARKET GROWTH DRIVERS:

Expansion of Comprehensive Cancer Screening Programs

The expansion of thorough cancer screening initiatives is a major factor influencing the ovarian cancer market. These initiatives focus on identifying cancer during its initial phases, allowing for more successful therapies and better patient results. Through the integration of gender-specific diagnostics, hereditary cancer risk assessment, and tumor markers, these initiatives offer a thorough strategy for cancer detection. As knowledge about the significance of early detection expands, the need for accessible and cost-effective screening options rises, especially in areas with increasing cancer rates. This broader access to screening services not only facilitates earlier intervention but also expands the market for diagnostic tools, driving the demand for innovative products and services in the ovarian cancer space. In 2025, Metropolis Healthcare launched the TruHealth Cancer Screen 360, a comprehensive cancer screening panel aimed at improving early cancer detection in India. The panel includes gender-specific diagnostics, hereditary cancer risk analysis, and tumor markers for multiple cancers. This initiative seeks to address the rising cancer burden, especially in urban and non-urban areas, by making screening more accessible and affordable.

Rise of Genetic Testing and Risk Assessment Initiatives

Enhanced emphasis on identifying individuals with greater genetic susceptibility allows for earlier identification and tailored prevention approaches. This transition towards proactive healthcare enables focused interventions, resulting in better outcomes and possibly lower incidence rates. With genetic testing becoming increasingly available, especially for at-risk individuals and their families, the need for associated diagnostic services, treatments, and educational resources grows. Moreover, these efforts enable patients to make knowledgeable choices regarding their health, ultimately supporting the market growth through heightened awareness and access to early detection tools. In 2024, Stanford Medicine received a $3.5 million legacy gift from Bright Pink to launch the Bright Pink Preventive Risk Outreach and Cascade Testing (PROACT) Program. The initiative aimed to increase genetic testing for breast and ovarian cancer, focusing on at-risk individuals and their families. The program builds on Bright Pink's previous work, making genetic risk assessments more accessible and empowering proactive health management.

Advancements in AI-Driven Cancer Research

The incorporation of artificial intelligence (AI) into ovarian cancer studies is propelling market growth by enhancing early detection, personalized treatment strategies, and accelerating research advancements. AI technologies allow for the examination of large datasets, revealing patterns and insights that were once challenging to discover. Utilizing machine learning (ML) algorithms on patient data enables researchers to create more precise diagnostic tools, enhance treatment protocols, and anticipate patient outcomes. As AI continues to transform research methodologies, it enhances the effectiveness of treatments and improves survival rates, thereby increasing the demand for innovative cancer care solutions and further supporting the market growth. In 2025, the Global Ovarian Cancer Research Consortium launched a $1 million AI Accelerator Grant in partnership with Microsoft's AI for Good Lab. The initiative aims to advance ovarian cancer research by using AI to improve survival rates. The grant will fund multi-country, multidisciplinary research teams to tackle the global ovarian cancer crisis.

OVARIAN CANCER INDUSTRY SEGMENTATION:

Breakup by Type:

  • Epithelial Ovarian Cancer
  • Germ Cell Ovarian Cancer
  • Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Surgery
  • Others

Immunotherapy is the most popular treatment type

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

  • Hospitals
  • Homecare
  • Speciality Centre
  • Others

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

COMPETITIVE LANDSCAPE:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • F. Hoffmann-La
  • Roche AG
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the ovarian cancer market?

2. What is the future outlook of the ovarian cancer market?

3. What are the key factors driving the ovarian cancer market?

4. Which region accounts for the largest ovarian cancer market share?

5. Which are the leading companies in the global ovarian cancer market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2025
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players